Crossmark

Epigenetic drug discovery: breaking through the immune barrier

Crossref DOI link: https://doi.org/10.1038/nrd.2016.185

Published Online: 2016-10-21

Published Print: 2016-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Tough, David F.

Tak, Paul P.

Tarakhovsky, Alexander

Prinjha, Rab K.
License Information

Text and Data Mining valid from 2016-10-21
More Information

Article History

First Online: 21 October 2016

Competing interests

: D.F.T., P.P.T. and R.K.P. are employees and shareholders of GlaxoSmithKline, which is involved in Research and Development of epigenetic inhibitors for the treatment of disease. A.T. has received research support and consultancy payments from GlaxoSmithKline.